Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 1, 2004, Pages 73-84

  Ding, Reinhard ^a   Tayrouz, Yorki ^a   Riedel, Klaus Dieter ^a   Burhenne, Jürgen ^a   Weiss, Johanna ^a   Mikus, Gerd ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; RITONAVIR;

ADULT; ANALYSIS; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME; VOLUNTEER;

ADULT; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; RITONAVIR;

EID: 3042568988     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.02.008     Document Type: Article

References (47)

1. Pierson T., McArthur J., Siliciano R.F. Reservoirs for HIV-1 mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 18:2000;665-708
2. van der Sandt I., Vos C.M., Nabulsi L., Blom-Roosemalen M.C., Voorwinden H.H., de Boer A.G., et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 15:2001;483-491
3. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M., Beijnen J.H., Schinkel A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 59:2001;806-813
4. Drewe J., Gutmann H., Fricker G., Toeroek M., Beglinger C., Huwyler J. HIV protease inhibitor ritonavir a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 57:1999;1147-1152
5. Gutmann H., Fricker G., Drewe J., Toeroek M., Miller D.S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 56:1999;383-389
6. Hsu A., Granneman G.R., Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 35:1998;275-291
7. Tayrouz Y., Ganssmann B., Ding R., Klingmann A., Aderjan R., Burhenne J., et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther. 70:2001;405-414
8. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M., et al. Protease inhibitors as inhibitors of human cytochromes P450 high risk associated with ritonavir. J Clin Pharmacol. 38:1998;106-111
9. Hinderling P.H., Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit. 13:1991;381-401
10. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 34:2002;47-54
11. Bonate P.L., Reith K., Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet. 34:1998;375-404
12. de Lannoy I.A., Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 189:1992;551-557
13. Koren G., Woodland C., Ito S. Toxic digoxin-drug interactions the major role of renal P-glycoprotein. Vet Hum Toxicol. 40:1998;45-46
14. Hori R., Okamura N., Aiba T., Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther. 266:1993;1620-1625
15. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of p-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 305:2003;197-204
16. Hager W.D., Fenster P., Mayersohn M., Perrier D., Graves P., Marcus F.I., et al. Digoxin-quinidine interaction. Pharmacokinetic evaluation. N Engl J Med. 300:1979;1238-1241
17. Rameis H. Quinidine-digoxin interaction are the pharmacokinetics of both drugs altered? Int J Clin Pharmacol Ther Toxicol. 23:1985;145-153
18. Steiness E., Waldorff S., Hansen P.B., Kjaergard H., Buch J., Egeblad H. Reduction of digoxin-induced inotropism during quinidine administration. Clin Pharmacol Ther. 27:1980;791-795
19. Pedersen K.E., Dorph-Pedersen A., Hvidt S., Klitgaard N.A., Nielsen-Kudsk F. Digoxin-verapamil interaction. Clin Pharmacol Ther. 30:1981;311-316
20. Kovarik J.M., Rigaudy L., Guerret M., Gerbeau C., Rost K.L. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther. 66:1999;391-400
21. Waldorff S., Hansen P.B., Egeblad H., Berning J., Buch J., Kjaergard H., et al. Interactions between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther. 33:1983;418-423
22. Rengelshausen J., Goggelmann C., Burhenne J., Riedel K.D., Ludwig J., Weiss J., et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 56:2003;32-38
23. Tanaka H., Matsumoto K., Ueno K., Kodama M., Yoneda K., Katayama Y., et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother. 37:2003;178-181
24. Wakasugi H., Yano I., Ito T., Hashida T., Futami T., Nohara R., et al. Effect of clarithromycin on renal excretion of digoxin interaction with P-glycoprotein. Clin Pharmacol Ther. 64:1998;123-128
25. Halkin H., Sheiner L.B., Peck C.C., Melmon K.L. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther. 17:1975;385-394
26. O'Brien M.S., Huston J.R., Reid R.J., Gibson T.P. Pitfalls in, and new methods for, the radioimmunoassay for digoxin in urine. Clin Chem. 31:1985;122-124
27. Koup J.R., Greenblatt D.J., Jusko W.J., Smith T.W., Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm. 3:1975;181-192
28. Sumner D.J., Russell A.J. Digoxin pharmacokinetics multicompartmental analysis and its clinical implications. Br J Clin Pharmacol. 3:1976;221-229
29. Phillips E.J., Rachlis A.R., Ito S. Digoxin toxicity and ritonavir a drug interaction mediated through p-glycoprotein? AIDS. 17:2003;1577-1578
30. Drescher S., Glaeser H., Murdter T., Hitzl M., Eichelbaum M., Fromm M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 73:2003;223-231
31. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 84:1987;7735-7738
32. Wandell M., Powell J.R., Hager W.D., Fenster P.E., Graves P.E., Conrad K.A., et al. Effect of quinine on digoxin kinetics. Clin Pharmacol Ther. 28:1980;425-430
33. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 28:2000;655-660
34. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M. Inhibition of P-glycoprotein-mediated drug transport a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 99:1999;552-557
35. Schenck-Gustafsson K., Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol. 11:1981;181-186
36. Doherty J.E., Straub K.D., Murphy M.L., de Soyza N., Bissett J.K., Kane J.J. Digoxin-quinidine interaction. Changes in canine tissue concentration from steady state with quinidine. Am J Cardiol. 45:1980;1196-1200
37. Huwyler J., Cerletti A., Fricker G., Eberle A.N., Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target. 10:2002;73-79
38. Srinivas R.V., Middlemas D., Flynn P., Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother. 42:1998;3157-3162
39. Olson D.P., Scadden D.T., D'Aquila R.T., De Pasquale M.P. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 16:2002;1743-1747
40. Miller D.S., Nobmann S.N., Gutmann H., Toeroek M., Drewe J., Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol. 58:2000;1357-1367
41. Zhang L., Gorset W., Washington C.B., Blaschke T.F., Kroetz D.L., Giacomini K.M. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 28:2000;329-334
42. Lowes S., Cavet M.E., Simmons N.L. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol. 458:2003;49-56
43. Stephens R.H., O'Neill C.A., Bennett J., Humphrey M., Henry B., Rowland M., et al. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br J Pharmacol. 135:2002;2038-2046
44. Koren G., Klein J., Giesbrecht E., Ben Dayan R., Soldin S., Sellers E., et al. Effects of quinidine on the renal tubular and biliary transport of digoxin in vivo and in vitro studies in the dog. J Pharmacol Exp Ther. 247:1988;1193-1198
45. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 120:2001;525-533
46. Konig J., Cui Y., Nies A.T., Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 275:2000;23161-23168
47. Aarnoutse R.E., Grintjes K.J.T., Telgt D.S.C., Stek M., Hugen P.W.H., Reiss P., et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 71:2002;57-67